Dyne Therapeutics Inc (DYN) - News Archive

BackgroundNeuromuscular diseases such as Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular Dystrophy (DMD) present significant challenges for patients and clinicians alike. These conditions are characterized by prog...

Dyne Therapeutics, a biotechnology company dedicated to creating transformative therapies for patients with serious muscle diseases, has announced significant advancements across multiple clinical programs. The company...

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe DiseaseWALTHAM, Mass., June 24, 2024 - Dyne Therapeutics...

Dyne Therapeutics Raises $374.3 Million in Public Offering, Continues to Advance Innovation in Muscle Disease TherapeuticsDyne Therapeutics Inc. announces the successful closing of its underwritten public offering of 12...

Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common StockWALTHAM, Mass., May 21, 2024 Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company, has recently disclosed th...

In a press release on May 20, 2024, Dyne Therapeutics, a clinical-stage muscle disease company, announced its intention to initiate an underwritten public offering. The offering aims to raise $300 million through the sa...

Dyne Therapeutics Achieves Breakthrough Results in Clinical Trials for DM1 and DMD, Driving Significant Biomarker Improvement and Enhanced Functional EndpointsDyne Therapeutics, a leading biotechnology company, recently...

In a groundbreaking move, Dyne Therapeutics, a prominent clinical-stage muscle disease company, recently announced its plans to release new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIVER clinical trials...

Dyne Therapeutics, a leading biotechnology company dedicated to developing novel therapies for patients with muscle diseases, recently announced the presentation of exciting initial clinical data from its ACHIEVE and DE...

Dyne Therapeutics, a clinical-stage muscle disease company specializing in genetic-driven disease therapeutics, has recently concluded its underwritten public offering of common stock, resulting in significant proceeds....

Dyne Therapeutics Announces Pricing of Public Offering, Significantly Boosting Shareholder ConfidenceWALTHAM, Mass., Jan. 04, 2024 Dyne Therapeutics, Inc. (Nasdaq:DYN), a leading muscle disease company, made a groundbre...

Dyne Therapeutics Plans Underwritten Public Offering of $175 Million in Common StockDyne Therapeutics, a clinical-stage muscle disease company specializing in therapeutics for genetically driven diseases, has recently a...

In an encouraging stride forward, Dyne Therapeutics has recently announced preliminary positive clinical data stemming from their ACHIEVE and DELIVER trials. These trials represent prospective shaping of the future, wit...